Integrating Incretin-Based Therapy into Type 2 Diabetes Management

This CME supplement is sponsored by Primary Care Education Consortium and the Primary Care Metabolic Group and was supported by an educational grant from Amylin Pharmaceuticals, LLC.


The glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors have quickly become important treatment options for persons with type 2 diabetes. This article reviews the differences among the 3 GLP-1R agonists and 4 DPP-4 inhibitors currently available and how these differences impact treatment individualization. Emphasis is placed on strategies to improve patient self-management with the GLP-1R agonists, particularly those related to nausea and vomiting and medication adherence.

Physicians and Physician Assistants – Click Here to Take the Test

Next Article: